Skip to content

Introducing Connected Performance: Learn about a better approach for specialty pharmacy care

Read

Diabetes | Education & Development

Beyond Weight Loss: Optimizing GLP-1 RA Therapy for Older Adults Using the Medicare Bridge Program

By Elliot Ogorek, Ambulatory Clinical Pharmacist, and Savannah McPherson, Therapy Management Clinical Pharmacist
•
November 17th, 2026

On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program, a pilot program designed to expand affordable access to GLP-1 receptor agonist (GLP-1 RA) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA medications for eligible Medicare Part D beneficiaries. Eligible members seeking treatment to reduce excess body weight or maintain weight reduction typically meet additional criteria based upon the beneficiary's BMI, age and comorbidities. The program excludes coverage for a variety of conditions that some Medicare Part D programs may already cover including type 2 diabetes mellitus (T2DM), moderate to severe obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and other eligible for GLP-1 RA therapy. The medications covered include semaglutide (Wegovy injections and tablets), tirzepatide (Zepbound KwikPen), and orforglipron (Foundayo tablets), and the program is currently scheduled to run through December 31, 2027.¹

Roughly 600,000 patients initiated GLP-1 RA treatment for weight loss or maintenance through the Bridge program within its first two months of implementation, and based on Medicare data from 2023, roughly 3.8 million people could be eligible for coverage under the program.²

As access to weight loss therapy expands among Medicare beneficiaries, many of whom are older adults, healthcare professionals should consider how age-related changes can shape each patient's experience with GLP-1 RA therapy. Taking these factors into account from the start can help support safer, more individualized care. For the most up-to-date information about the Bridge program and its requirements/exclusions, please reference the CMS website directly: Medicare GLP-1 Bridge; CMS 

Muscle Loss and Fall Risk 

Aging adults are at increased risk for sarcopenia, the age-related loss of skeletal muscle mass and strength. Most importantly, sarcopenia involves the loss of muscle function, which can impair mobility, independence, and quality of life while increasing the risk of frailty, falls, hospitalization, and mortality.³

Helping patients understand and prepare for potential muscle loss is an important part of supporting them as they begin GLP-1 RA therapy. Although these medications can promote meaningful weight loss, not all the weight lost is body fat. Research suggests that approximately 75% of weight loss comes from fat mass and 25% from lean tissue, including muscle. Preserving muscle mass is therefore a critical component, especially in older adults who may already have reduced muscle reserves.⁴

Muscle mass reduction can also contribute to reduced bone density and increased fracture risk, negatively impacting physical function and independence. Additionally, age-related appetite decline combined with GLP-1 RA-mediated appetite suppression may make it more difficult for older adults to consume enough calories, specifically protein, to support muscle maintenance and prevent nutritional deficiencies.⁵

Patients are encouraged to focus on two key strategies to minimize muscle loss during GLP-1 RA treatment: 

  • Adequate protein intake (1.0-1.2 g/kg/day) to support muscle preservation; these general targets may not be appropriate for patients with heart failure, chronic kidney disease, or other conditions requiring fluid or protein restriction; individualize goals with the treating clinician.⁶ 

  • Regular strength training or weight-bearing exercises at least 3 times weekly plus at least 150 min of moderate-intensity aerobic exercise weekly to stimulate muscle maintenance and growth⁷

Both are vital, as neither nutrition nor exercise alone is sufficient to fully preserve muscle mass. Strength-training exercises using resistance bands, hand weights, or body weight, along with aerobic and balance activities, can help maintain strength, mobility, and functional independence as patients lose weight.⁵ 

For some older adults, starting resistance training can feel overwhelming. Meeting patients where they are can make these recommendations more attainable and sustainable. For example, chair yoga or water aerobics are two low-impact options that may feel more accessible to those new to fitness. Additionally, clinicians can use motivational interviewing techniques to help patients uncover their overall goals in taking GLP-1 RAs, whether that is being able to pick up their grandchildren or being able to walk upstairs without taking breaks. Connecting care to these individual goals can help patients stay engaged throughout treatment. 

Nutritional Deficiencies 

Nutritional deficiencies, often caused by appetite suppression, early satiety, and gastrointestinal (GI) adverse effects like diarrhea and vomiting, can substantially reduce food intake, making it difficult to meet vital protein, fiber, vitamin, and mineral requirements. Clinicians should help patients distinguish between intentional calorie reduction and inadequate nutritional intake and consider referral to a registered dietitian, nutritionist, or diabetes educator when appropriate.⁵

Protein intake is particularly important to help preserve muscle mass and physical function during weight loss. The PROT-AGE Study Group recommends 1.0-1.2 g/kg/day of protein for most older adults attempting weight loss, which generally translates to 25-30 g of protein per meal. Patients can be encouraged to consume protein-rich foods first at meals, emphasizing nutrient-dense options such as eggs, fish, Greek yogurt, cottage cheese, legumes, nuts, seeds, and lean poultry. When dietary intake is inadequate, protein supplements, shakes, or fortified products may help bridge nutritional gaps. Additionally, dietary supplements can be proactively considered for at-risk nutrients, such as vitamin D, calcium, vitamin B12, or a multivitamin-mineral tablet, at appropriate doses and tailored to each person’s needs.⁶

Bone Loss Concerns 

Bone health discussions warrant special attention in older adults taking GLP-1 RAs. Weight loss can reduce mechanical loading on the skeleton and contribute to decreased bone mineral density. Specifically, rapid or substantial weight reduction may be associated with greater bone loss, particularly in older adults and women.⁸

Studies have shown that weight loss is associated with decreased bone mineral density, which can increase the risk of osteopenia or osteoporosis. Encouragingly, resistance training may help preserve bone health, showcasing the importance of incorporating strength-based exercises while taking a GLP-1 RA.⁸'⁹

Baseline assessment of fracture risk, vitamin D status, and consideration of bone density screening (DEXA scan) may be appropriate when initiating GLP-1 RA therapy in older adults and helpful for monitoring during treatment.⁹

Dehydration  

Older adults starting GLP-1 RA medications should receive education on the importance of maintaining adequate hydration, as this population is prone to dehydration. GI adverse effects such as nausea, vomiting, diarrhea, and constipation can decrease both food and fluid intake. Older adults are already predisposed to dehydration because aging can be associated with a diminished thirst response. These factors can make modest reductions in fluid intake clinically significant. The principle of “start low and go slow” is particularly important when dosing GLP-1 RA medications for older adults to mitigate side effect risk. Doses are titrated per prescribing guidance; prescribers may slow escalation based on tolerability.⁹'¹⁰

Maintaining adequate daily fluid intake thus becomes vital when taking GLP-1 RAs. The National Academy of Medicine recommends approximately 13 cups (~100 oz) of fluids daily for most men and 9 cups (~70 oz) daily for most women age 51 and older. Clinicians should encourage patients to drink on a schedule rather than relying solely on thirst cues and should incorporate water-rich foods such as fruits, vegetables, soups, and broths when thirst is reduced.¹¹

Polypharmacy 

Older adults are commonly diagnosed with multiple comorbidities and often require complex medication regimens, including diuretics, SGLT2 inhibitors, and other medications that impact fluid balance. If these patients experience GI side effects resulting from GLP-1 RA use, they are often compounded, leading to an additive risk of dehydration, hypotension (fall risk), and acute kidney injury.​¹²

GLP-1 RAs also delay gastric emptying, which may impact the absorption and tolerability of some oral medications. Additionally, while GLP-1 RAs carry a low risk of hypoglycemia by themselves, concomitant use with certain medications may necessitate closer monitoring and dose adjustments to prevent low blood sugar levels.⁵'¹³

Pharmacist-led medication reconciliation is particularly valuable in this population to identify potential interactions, evaluate dehydration-related risks, and anticipate changes in medications as weight loss leads to improved glycemic control. 

Conclusion 

The Medicare GLP-1 Bridge program has expanded access to GLP-1 RA weight-management therapies for many aging adults. However, successful treatment is more than the number on the scale. It is about helping patients improve their overall health while maintaining strength, mobility, and independence that matter in their everyday lives. 

Preserving muscle mass and function, maintaining adequate nutrition and hydration, protecting bone health, minimizing fall risk, and carefully managing polypharmacy are all important to achieving meaningful, sustainable outcomes. 

As use of GLP-1 RAs continues to grow among Medicare beneficiaries, pharmacists will continue to play a critical role in helping patients navigate treatment safely and successfully. Through ongoing education, medication management, and collaboration across the care team, pharmacists can help identify risks early and ensure treatment continues to support each patient's health, well-being, and quality of life. 

Disclaimer: This is educational content for healthcare professionals, not medical advice. Please refer to the specific medication prescribing information for the most up-to-date data pertaining to safety.  

​​

References 

​​1. Services, Centers for Medicare and Medicaid. Centers for Medicare & Medicaid Services. CMS.gov. [Online] November 11, 2026. [Cited: November 11, 2026.] https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. 

​2. Reuters. [Online] August 31, 2026. https://www.reuters.com/legal/litigation/600000-seniors-have-signed-up-obesity-drugs-under-new-medicare-program-2026-08-31/. 

​3. Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? K. Prokopidis, R. Daly, C. Suetta. 2025, The Journal of Nutrition, Health, and Aging, p. 100652. 

​4. Weight Loss Composition is One-Fourth Fat-Free Mass: A Critical Review and Critique of This Widely Cited Rule. S. Heymsfield, M. Gonzalez, W. Shen, L. Redman, D. Thomas. 2014, Obesity Review, pp. 310-321. 

​5. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA. 8, Aug 2025, Obesity, Vol. 33, pp. 1475-1503. 

​6. Managing obesity in older adults. Sundaresh S, Saliba S, Ziyadeh F, Mauer Y, Valencia WM. 11, Nov 2025, CLeve CLin J Med, Vol. 92, pp. 686-692. 

​7. GLP-1 agonists and exercise: the future of lifestyle prioritization. R. Codella, P. Senesi, L. Luzi. 2025, Frontiers in Clinical Diabetes and Healthcare. 

​8. Sarcopenic obesity in older adults: a clinical overview. Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. 5, Feb 2024, Nat Rev Endocrinoly, Vol. 20, pp. 261-277. 

​9. Expert Consensus on the Management of Obesity in Older Adults (2026 Edition). Qi Pan, Lixin Guo. 4, Sep 2026, Aging Med (Milton), Vol. 9, pp. 355-369. 

​10. The European Society for Clinical Nutrition and Metabolism (ESPEN) Guideline on Clinical Nutrition and Hydration in Geriatrics. Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Hooper L, Kiesswetter E, Maggio M, Raynaud-Simon A, Sieber C, Sobotka L, van Asselt D, Wirth R, Bischoff SC, Cuesta Triana F, Palma Milla S, Ramos-Acevedo S, Serralde-Zúñiga AE, Sánchez-Rodríguez D, López-C. 2, Apr 2026, The Dietitians and Nutritional Research Unit, EATEN; Spanish Journal of Geriatrics and Gerontology, Vol. 43, pp. 418-461. 

​11. Water., Institute of Medicine (U.S.). Panel on Dietary Reference Intakes for Electrolytes and. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate ; Panel on Dietary Reference Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Washington, D.C : National Academies Press, 2005. 

​12. Effects of Drugs and Excipients on Hydration Status. Puga AM, Lopez-Oliva S, Trives C, Partearroyo T, Varela-Moreiras G. 3, Mar 2019, Nutrients, Vol. 11, p. 669. 

​13. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Committee, American Diabetes Association Professional Practice. 2025, Diabetes Care, pp. S181-S206. 

​​​